Cannabis Use

Introduction

Cannabis is the most widely produced and consumed illicit psychoactive substance globally.^[1] While often used occasionally, it can progress to frequent use, abuse, and dependence, with approximately 1 in 10 occasional users developing dependence.^[1] This progression is associated with various adverse physical, psychological, social, and occupational consequences.^[1] Despite its increasing use for medicinal purposes, research continues to report associations with negative health outcomes.^[1]

Biological Basis

Individual differences in the risk of lifetime cannabis use are evident, and studies have shown that genetic factors play a significant role. Twin studies estimate the heritability of cannabis use initiation to be between 40% and 48% for males and females, respectively.^[1] Beyond genetics, shared environmental factors, such as cannabis availability and parental monitoring, also contribute substantially to this risk, accounting for 25% to 39% of the risk for males and females, respectively.^[1]There is also a notable overlap in the genetic risks underlying lifetime cannabis use and cannabis use disorder.^[1] Early genetic studies, including genome-wide linkage and candidate gene approaches (e.g., involving genes like CNR1, GABRA2, FAAH, and ABCB1), faced challenges with inconsistent findings and a lack of genome-wide significance or replication.^[1]More recently, large-scale genome-wide association studies (GWAS) have aimed to identify specific genetic risk variants. A meta-analysis by the International Cannabis Consortium, involving over 32,000 subjects, revealed that while no single SNP reached genome-wide significance, common SNPs collectively explained 13% to 20% of the variation in lifetime cannabis use.^[1]Other studies have estimated SNP-based heritability for lifetime cannabis use to be around 6% to 25%.^[1]Further research has uncovered genetic correlations between lifetime cannabis use and a broad range of other traits. For instance, a strong genetic correlation (rg = 0.83) exists with lifetime cigarette smoking.^[1]Genetic correlations have also been identified with 25 other traits, including nicotine, alcohol, and caffeine use, as well as psychiatric conditions such as schizophrenia, depression, and bipolar disorder.^[2]Genes implicated in cannabis use phenotypes have shown previous associations with other traits, including schizophrenia (e.g.,TUFM, NCAM1), BMI or obesity (e.g.,SH2B1, APOBR, ATXN2L), alcohol use (e.g., ALDH2), intelligence (CNNM2, CCDC101), and externalizing/impulsive phenotypes (HTR1A).^[2]

Clinical Relevance

The adverse health effects associated with cannabis use are clinically significant, particularly the increased risk for psychiatric outcomes such as psychosis, schizophrenia, schizotypal personality disorder, and mania.^[1]Early cannabis use may also influence the relationship between polygenic risk scores for schizophrenia and brain maturation.^[1]Understanding the genetic underpinnings of cannabis use is therefore considered a public health priority, especially given the established phenotypic associations between cannabis use and psychiatric disorders, as well as other substance use.^[1]

Social Importance

As cannabis remains the most widely produced and consumed illicit psychoactive substance globally, its societal impact is substantial.^[1] The expanding medicalization and decriminalization of cannabis further highlight the need for a comprehensive understanding of its effects, making the study of its genetics a critical public health concern.^[1]The influence of shared environmental factors like availability and parental monitoring also underscores the complex interplay between genetic predispositions and social context in shaping cannabis use patterns.^[1]

Methodological and Statistical Power Constraints

Genetic studies of cannabis use have faced challenges related to statistical power and study design. Earlier genome-wide association studies (GWAS) were often underpowered to detect the small effect sizes typical of common genetic variants underlying highly polygenic traits, leading to an absence of genome-wide significant associations.^[1]Power analyses indicate that a substantial increase in sample size, potentially a twofold increase, is necessary to reliably detect genetic variants with modest effect sizes (e.g., odds ratios of 1.1).^[1] This insufficient power also contributes to difficulties in replicating findings across different cohorts, where a lack of statistical power has been identified as a likely reason for replication failures.^[3] The study design itself has introduced variability, as the mean age at initiation and the degree of censoring varied across cohorts, influenced by differences in sampling, assessment methods, drug policy, legality, and availability.^[3]Furthermore, the prevalence of lifetime cannabis use ranged widely between cohorts, from 1% to 92%, reflecting diverse sample characteristics, recruitment strategies, and socio-political contexts.^[1]While meta-analyses adjust for some cohort-specific factors like birth cohort effects, the use of a dichotomous measure for lifetime cannabis use, which conflates single, regular, and problematic use patterns, can reduce the power to detect specific genetic associations.^[1]

Phenotypic Heterogeneity and Generalizability

A key limitation in understanding the genetics of cannabis use stems from the inherent heterogeneity in how the phenotype is defined and measured. Studies often rely on broad, dichotomous classifications like “lifetime cannabis use” or “age at first use,” which may obscure more nuanced patterns of consumption, such as frequency, quantity, or the development of abuse or dependence.^[1]Although consistent across samples, the phrasing of questions regarding cannabis use could differ slightly between studies.^[1]Additionally, the lack of collected information on cannabis use opportunities is a recognized limitation, as a high genetic risk for drug use may not manifest without the opportunity for exposure.^[3] The generalizability of current findings is also constrained by the demographic characteristics of the study populations. Many large-scale genetic analyses, including meta-analyses, have been limited to individuals of European ancestry.^[3] This ancestral restriction means that the conclusions drawn from these studies, including the identified genetic loci and their estimated effects, may not be applicable to populations of other ethnicities. Further research across diverse ancestral groups is essential to determine the broader applicability of these genetic insights.

Genetic Complexity and Environmental Influences

Despite evidence from twin studies indicating a significant heritable component for cannabis use, a substantial portion of this genetic variation, particularly for age at first use, remains unexplained by common genetic variants captured on current GWAS arrays.^[3] This “missing heritability” suggests that other sources of genetic variation, such as rare mutations (with minor allele frequencies less than 0.05), non-additive genetic variance, epistasis, or complex gene-gene interactions, may play a crucial role that is not fully captured by current methodologies and sample sizes.^[1]Furthermore, genetic predispositions to cannabis use do not operate in isolation but are influenced by complex interactions with environmental factors. Studies acknowledge that genetic variants interact with environmental risk factors, and that unmeasured or unharmonized environmental exposures, such as cultural differences, drug availability, and policy variations between countries, can confound genetic association analyses.^[1]Detecting these intricate gene-environment interactions, including the critical factor of cannabis use opportunities, requires larger sample sizes and standardized, comprehensive measures of environmental exposures across all contributing cohorts.^[3]

Variants

Genetic variations play a crucial role in an individual’s predisposition to various traits, including those related to cannabis use. Several genes and their specific single nucleotide polymorphisms (SNPs) have been identified through genome-wide association studies (GWAS) as being associated with lifetime cannabis use or related behavioral phenotypes. These variants often impact neural development, signaling pathways, and personality traits that may influence the likelihood of cannabis initiation or continued use.

One prominently identified gene is NCAM1 (Neural Cell Adhesion Molecule 1), which encodes a cell adhesion protein vital for cell-cell contact and is a member of the immunoglobulin superfamily.^[4] NCAM1 is part of the NCAM1–TTC12–ANKK1–DRD2 (NTAD) gene cluster, which is involved in neurogenesis and dopaminergic neurotransmission, pathways critical for brain development and reward processing.^[1] Variants like rs9919557 and rs11214470 within NCAM1may influence its expression or function, thereby modulating neuronal connectivity and potentially affecting an individual’s susceptibility to substance use. The gene has been strongly linked to lifetime cannabis use and other substance use phenotypes, including nicotine and alcohol dependence, suggesting a broader role in addiction vulnerability.^[1]Another significant gene associated with cannabis use isCADM2 (Cell Adhesion Molecule 2), a synaptic cell adhesion molecule also belonging to the immunoglobulin superfamily.^[1] CADM2 variants, such as rs2875907 and rs1368740 , have shown strong associations with lifetime cannabis use, withrs2875907 specifically regulating CADM2 expression in non-brain tissues.^[4]This gene is implicated in a wide array of behavioral phenotypes, including processing speed, body mass index, alcohol consumption, and personality traits like reduced anxiety, neuroticism, and conscientiousness, alongside increased risk-taking behavior.^[1] The association of CADM2with cannabis use may stem from its influence on these underlying personality characteristics, which are known to correlate with substance use.

Other variants linked to cannabis use includers13107325 in SLC39A8, which encodes a zinc transporter essential for cellular zinc homeostasis, a process vital for neurotransmission and brain development. Similarly, rs9387013 is located within TRAF3IP2-AS1, an antisense RNA that may regulate the expression of TRAF3IP2, a gene involved in immune and inflammatory responses, potentially influencing neuroinflammation or stress pathways relevant to substance use. The variant rs1579547 is found in the region of TMEM182 and CRLF3P1, where TMEM182 encodes a transmembrane protein with roles in cell signaling, while CRLF3P1 is a pseudogene whose regulatory elements might impact neighboring gene activity. Variants like rs6438436 in the LSAMP - IGSF11 region are also of interest; LSAMP is a neuronal cell adhesion molecule involved in brain development and function, and alterations could affect neural circuit formation. Furthermore, rs11210887 in PTPRF, a gene encoding a receptor-type protein tyrosine phosphatase, could impact neuronal signaling and synaptic plasticity. The variant rs8039398 in SEMA6D involves a semaphorin family member known to guide axon growth and neuronal migration, potentially influencing brain connectivity. Lastly, rs1004787 in LINC01833 and rs74760947 in the RPL10AP3 - LINC01288 region involve long non-coding RNAs and pseudogenes, respectively, which can exert regulatory control over gene expression and cellular processes critical for brain function and behavior.

Key Variants

RS ID	Gene	Related Traits
rs9919557 rs11214470	NCAM1	cannabis use major depressive disorder
rs13107325	SLC39A8	body mass index diastolic blood pressure systolic blood pressure high density lipoprotein cholesterol measurement mean arterial pressure
rs2875907 rs1368740	CADM2	cannabis use
rs9387013	TRAF3IP2-AS1	cannabis use
rs1579547	TMEM182 - CRLF3P1	cannabis use
rs6438436	LSAMP - IGSF11	cannabis use smoking status measurement restless legs syndrome
rs11210887	PTPRF	self reported educational attainment smoking initiation cannabis use attention deficit hyperactivity disorder risk-taking behaviour
rs8039398	SEMA6D	cannabis use attention deficit hyperactivity disorder attention deficit hyperactivity disorder, major depressive disorder
rs1004787	LINC01833	social inhibition quality, attention deficit hyperactivity disorder, substance abuse cannabis use brain attribute smoking status measurement smoking behavior
rs74760947	RPL10AP3 - LINC01288	cannabis use attention deficit hyperactivity disorder attention deficit hyperactivity disorder, autism spectrum disorder, intelligence attention deficit hyperactivity disorder, major depressive disorder

Defining Cannabis Use: Initiation, Engagement, and Cessation

The term ‘cannabis use’ broadly encompasses an individual’s engagement with cannabis, ranging from initial experimentation to sustained consumption and eventual cessation. A fundamental aspect is “cannabis use initiation,” which defines whether an individual has “ever used cannabis” or “never used cannabis”.^[3] This is often operationalized as a dichotomous phenotype, typically assessed by asking about the age at which an individual first experimented with cannabis or tried “soft drugs such as hashish or cannabis”.^[3]“Lifetime cannabis use” is a related and widely utilized definition, categorizing individuals based on a simple yes/no response to having ever consumed cannabis during their life.^[2]Beyond initiation, the concept of “cannabis use cessation” refers to the discontinuation of cannabis consumption following a period of use.^[5] The frequency and duration of use are also critical definitional elements, with studies often quantifying “frequency of use” over specific periods, such as the past three months or standardized to days of use in the last 30 days.^[5]“Age at first cannabis use,” also known as “age of cannabis use onset,” is another key metric, indicating the age at which an individual first consumed cannabis.^[3] These precise definitions are essential for epidemiological studies and genetic research, allowing for consistent measurement and comparison across diverse populations.

Spectrum of Cannabis Engagement: From Use to Disorder

Cannabis engagement exists on a spectrum, moving beyond simple use to encompass more clinically significant patterns, including problematic use, abuse, and dependence. “Problematic cannabis use” refers to patterns of consumption that lead to negative consequences or impairment.^[6]More severe classifications include “cannabis abuse” and “cannabis dependence,” which historically represented distinct diagnostic categories within nosological systems like the DSM (Diagnostic and Statistical Manual of Mental Disorders).^[7] These classifications denote escalating levels of severity based on specific diagnostic criteria, such as persistent use despite adverse consequences, tolerance, or withdrawal symptoms.^[8]The contemporary understanding often consolidates these into “cannabis use disorders,” which acknowledge the growing prevalence and clinical impact of these conditions.^[3]Research indicates that “lifetime cannabis use” shares significant genetic risks with the propensity for cannabis abuse or dependence, highlighting a genetic continuum underlying these related phenotypes.^[1] This categorical-dimensional approach allows for both broad population-level assessment of use and detailed clinical evaluation of individuals experiencing significant impairment, informing both public health strategies and personalized interventions.

Operationalizing Cannabis Use for Research and Clinical Assessment

Operational definitions and measurement approaches are crucial for consistently assessing cannabis use in research and clinical settings. Data on cannabis use is commonly collected through “self-reported history,” utilizing various survey instruments.^[5] These instruments may include multiple-choice questions, such as “At which age did you experiment with cannabis for the first time?”, or open-ended questions like “Have you ever tried hashish or cannabis? If yes, at which age?”.^[3] For quantifying frequency, some studies employ detailed scales, such as an eight-category scale ranging from ‘never’ to ‘more than 40 times’ over specified periods (e.g., whole life, last 12 months, last 4 weeks).^[3] In research, raw frequency measures are often “recategorized as ordered factored variables” to facilitate statistical analysis.^[5]For genetic association studies, phenotypes like “lifetime cannabis use” are typically operationalized as a dichotomous variable (e.g., yes=1 versus no=0) to maximize sample size and power to detect genetic variants.^[1]These standardized measurement approaches and operational definitions ensure that data collected across different cohorts and studies can be aggregated and compared, providing a robust foundation for understanding the genetic and environmental influences on cannabis use.

Patterns of Cannabis Use and Associated Clinical Manifestations

Cannabis use is common, with surveys indicating that approximately one in five Europeans aged 15–64 and an estimated 51.6% of individuals aged 16–34 in the United States have experimented with cannabis.^[9]Clinical presentations of cannabis use range from recreational initiation to problematic use and abuse, which can be assessed through self-reported lifetime use (ever/never), age at first use, and frequency scales (e.g., an eight-category scale ranging from ‘never’ to ‘more than 40 times’ over various timeframes, often collapsed into a dichotomous phenotype for research).^[9]Regular use is associated with several adverse health effects, including mood and anxiety disorders, chronic bronchitis, and possible negative impacts on cognitive functioning, particularly with early onset during adolescence.^[9]The severity of cannabis use can progress, with about 9% of those who initiate cannabis use advancing to regular use and abuse.^[9]A significant clinical concern is the elevated risk of psychotic symptoms, which is further amplified with daily use of high-potency cannabis, potentially triggering first-episode psychosis.^[9]Beyond psychiatric and respiratory issues, early and regular cannabis use can also predict diminished educational and professional attainment, highlighting the broad impact of problematic use patterns.^[9]

Heterogeneity in Cannabis Use Liability and Genetic Underpinnings

Inter-individual variation in the liability to initiate cannabis use and its progression is substantial, influenced by both genetic and environmental factors.^[9]Twin and family studies demonstrate that additive genetic factors account for nearly half the variance in the liability to initiate cannabis use, specifically 48% in females and 40% in males, with environmental factors contributing to the remainder.^[9]Age at first cannabis use is a critical variable, as early onset is associated with an increased likelihood of progressing to other drug use.^[10]Assessment of this heterogeneity often involves collecting data on age at phenotypic assessment, sex, and birth cohort.^[1] Advanced measurement approaches, such as genome-wide association studies (GWAS) and gene-based analyses, have begun to pinpoint specific genomic regions and genes, like ZNF181 and ZNF766 on chromosome 19, that show strong association signals with cannabis initiation.^[9]These genetic studies help to quantify the heritability of cannabis use phenotypes and identify the underlying biological pathways contributing to individual differences in susceptibility.^[9]

Diagnostic Significance and Overlap with Other Conditions

Understanding the causes of individual differences in cannabis use liability holds significant diagnostic value due to its well-established associations with adverse health effects and the risk of psychosis.^[9] A multi-stage model, encompassing cannabis availability, initiation, and progression to abuse, provides a framework for identifying individuals at higher risk.^[11]Clinically, cannabis use is phenotypically correlated with various psychiatric disorders, including schizophrenia, mood and anxiety disorders, and attention-deficit/hyperactivity disorder (ADHD), as well as with the use of other substances.^[2]Genetic correlation analyses, such as cross-trait LD-Score regression, further reveal shared genetic influences between lifetime cannabis use and a spectrum of mental health and substance use traits.^[2]These include schizophrenia, depression, bipolar disorder, alcohol use, nicotine dependence, and even traits like BMI, intelligence, and impulsive phenotypes.^[2]Genes identified in cannabis use GWAS, such asTUFM and NCAM1(associated with schizophrenia),SH2B1(BMI/obesity),ALDH2 (alcohol use), and HTR1A (alcohol and nicotine co-dependence, psychiatric disorders), underscore the complex genetic overlap, offering potential prognostic indicators and guiding differential diagnoses in clinical practice.^[2]

Genetic Predisposition

Individual differences in cannabis use are substantially influenced by genetic factors, with twin studies estimating the heritability of lifetime cannabis use to be between 40% and 48%.^[12] This heritable component is largely polygenic, meaning numerous genetic variants, each with a small effect, collectively contribute to an individual’s susceptibility.^[12] Early genome-wide association studies (GWAS) and linkage analyses identified suggestive regions but often lacked the power to achieve genome-wide significance, highlighting the need for larger meta-analytic samples to detect these subtle genetic influences.^[12]More recent and extensive GWAS efforts have begun to uncover specific genetic loci associated with cannabis use. While candidate gene studies targeting genes likeCNR1, GABRA2, FAAH, and ABCB1 have shown inconsistent associations, large-scale meta-analyses have revealed a genetic architecture involving variants distributed across the genome.^[12]These studies also suggest the potential contribution of rare genetic variants with larger effects that are not fully captured by common single-nucleotide polymorphisms (SNPs).^[9]Furthermore, there is substantial genetic overlap between lifetime cannabis use and cannabis use disorder, indicating shared underlying genetic vulnerabilities.^[12] Genes such as CHRNA2and neurodevelopmental genes likeFOXP2, PTPRF, or SEMA6Dhave been implicated in cannabis use risk.^[13]

Environmental and Developmental Influences

Beyond genetic factors, environmental influences play a significant role in determining cannabis use patterns. Shared environmental factors, such as the availability of cannabis and the level of parental monitoring, contribute considerably to an individual’s risk, accounting for approximately 25% to 39% of the variance in males and females, respectively.^[12]The remaining variance in cannabis use liability is almost equally attributed to both shared and unshared environmental factors.^[9] Developmental timing is also crucial, as early initiation and regular use during adolescence have been linked to potential negative outcomes. These include possible effects on cognitive functioning and a prediction of diminished educational and professional attainment.^[9]Moreover, genetic predispositions can interact with environmental exposures; for instance, early cannabis use has been observed to moderate the relationship between polygenic risk scores for schizophrenia and brain maturation, illustrating complex gene-environment interactions in shaping vulnerability.^[12]

Comorbidity and Genetic Overlap with Other Conditions

Cannabis use is frequently observed alongside other psychiatric and substance use disorders, pointing to shared underlying vulnerabilities and genetic overlaps. It is strongly associated with various adverse mental health outcomes, including psychosis and schizophrenia.^[2]Research indicates a significant genetic correlation between lifetime cannabis use and a wide spectrum of other complex traits, including other substance uses like nicotine, alcohol, and caffeine, as well as mental health conditions such as schizophrenia, depression, and bipolar disorder.^[2]This intricate network of genetic correlations suggests that individuals predisposed to certain psychiatric conditions may also have an increased susceptibility to cannabis use. Notably, studies have even identified a causal influence of schizophrenia on cannabis use, further underscoring the complex interplay between these conditions.^[2]Furthermore, a genetic overlap and potential causal relationship have been identified between Attention-Deficit/Hyperactivity Disorder (ADHD) and lifetime cannabis use.^[14]suggesting that genetic factors contributing to ADHD may also contribute to cannabis use.

Pharmacogenetics of Cannabis Use

Genetic variations play a significant role in an individual’s propensity for cannabis use, their response to cannabis, and the associated risks. Studies have shown that individual differences in lifetime cannabis use are substantially heritable, with estimates around 40-48% in twin studies, and approximately 25% of the variance explained by single-nucleotide polymorphisms (SNPs) in genome-wide association studies (GWAS).^[1]While identifying specific SNPs with large effects has been challenging due to the polygenic nature of complex traits, gene-based analyses have highlighted several genes and biological pathways involved in cannabis use phenotypes.^[1]

Genetic Influences on Cannabis Metabolism and Disposition

Pharmacogenomic research indicates that variants in drug metabolism enzymes can influence the pharmacokinetic profile of cannabis compounds, such as cannabinoids. While the provided studies do not directly detail cannabis metabolism by specific enzymes, they reference genes involved in broader drug metabolism. For instance, the cytochrome P450 enzyme CYP2A6 has been linked to smoking behavior.^[15] Given that cytochrome P450 enzymes are crucial for metabolizing many drugs and xenobiotics, including cannabinoids, variations in CYP2A6 and other P450 enzymes could theoretically alter the rate at which cannabis compounds are processed and eliminated from the body, thereby affecting their duration and intensity of action. Similarly, ALDH2(aldehyde dehydrogenase 2), a phase II enzyme, has been associated with alcohol use and also identified in gene-based analyses for cannabis use.^[2] Genetic variants in enzymes like ALDH2 could influence the metabolism of cannabis-derived aldehydes or other psychoactive substances, potentially impacting individual metabolic phenotypes and subsequent drug efficacy or adverse reactions.

Genetic Modulators of Cannabis Response and Addiction Risk

Variations in drug target genes and signaling pathways significantly influence an individual’s pharmacodynamic response to cannabis and their risk for developing problematic use. Several receptor genes have been implicated, including HTR1A, which encodes the serotonin 1A receptor, linked to cannabis use, alcohol and nicotine co-dependence, psychiatric disorders, and even response to antipsychotic treatments.^[2] Polymorphisms in HTR1A could alter serotonin signaling, impacting mood, reward pathways, and susceptibility to addiction. Nicotinic acetylcholine receptor subunits, such as those encoded by CHRNB3-CHRNA6 and CHRNA2, have also been associated with smoking behavior and cannabis use disorder, respectively.^[15]These receptor variants may modulate neurotransmitter systems involved in reward and addiction, leading to altered drug efficacy, a heightened risk for adverse reactions, or a different therapeutic response in individuals. Furthermore, potassium signaling has been suggested to play a role in addiction, indicating that genetic variations affecting ion channels or related pathways could influence the neurobiological response to cannabis.^[1]

Clinical Implications and Personalized Approaches

The growing understanding of cannabis pharmacogenetics holds promise for personalized prescribing and risk assessment, though clinical implementation is still in early stages. Identifying genetic variants in genes such as ZNF181, ZNF766, ATP2C2, CSDM1, and SLC35G1, which have been pinpointed in gene-based analyses for cannabis initiation and dependence, could help identify individuals at higher risk for developing problematic cannabis use.^[3]Moreover, the genetic overlap between cannabis use and psychiatric conditions like schizophrenia, depression, and ADHD, further highlights the importance of genetic screening.^[14] For instance, variants in genes like TUFM and NCAM1, associated with both cannabis use and schizophrenia, could inform clinicians about increased vulnerability to adverse psychiatric outcomes in certain individuals.^[2]While specific dosing recommendations or drug selection guidelines based on cannabis pharmacogenetics are not yet established, these findings lay the groundwork for future personalized interventions aimed at mitigating risks and optimizing outcomes related to cannabis use.

Global Prevalence and Demographic Patterns

Cannabis stands as one of the most frequently used substances among adolescents and young adults globally, with an estimated 147 million people, or 2.5% of the world’s population, consuming it annually.^[3]Over the past decade, cannabis use disorders have shown a more rapid increase than those for cocaine or opiates, particularly in developed regions such as North America, Western Europe, and Australia.^[3]These trends are accompanied by a global tendency towards a decreasing age at first cannabis use, with younger birth cohorts exhibiting a higher likelihood of initiating use.^[3]For instance, in the United States, the mean age at first cannabis use is 18 years, dropping to 16 years among individuals who initiate prior to age 21.^[3]European data further suggest a correlation where countries with higher cannabis use prevalence also report a lower mean age at first use, and the traditional male-female gap in initiation is narrowing in more recent cohorts, likely reflecting lower perceived risks and increased availability due to changing policies.^[3]

Large-Scale Genetic Investigations and Methodologies

Population studies on cannabis use extensively leverage large-scale genetic cohorts, biobanks, and meta-analyses to identify underlying genetic factors. The International Cannabis Consortium (ICC) has been instrumental, combining data from numerous cohorts across Europe, the United States, and Australia, involving tens of thousands of individuals.^[1]For instance, a meta-analysis on lifetime cannabis use included 32,330 individuals of European ancestry from 13 discovery samples, with participants ranging from 16 to 87 years old, and a replication phase involving 5,627 subjects.^[1] Other significant contributions come from large biobanks and genetics companies, such as the UK-Biobank, which provided data for 126,785 individuals, and 23andMe Inc., contributing data from 22,683 individuals, all predominantly of European ancestry.^[2]These studies typically employ rigorous methodologies, including genome-wide association studies (GWAS) with extensive quality control for single-nucleotide polymorphisms (SNPs) and subjects, genotype imputation using reference panels like 1000 Genomes, and statistical adjustments for covariates such as age, sex, birth cohort, and population stratification using principal components.^[3]These large-scale genetic analyses have revealed that common SNPs can explain between 13% and 20% of the variation in lifetime cannabis use, indicating a significant heritable component.^[1]While the phrasing of cannabis use questions might vary slightly across cohorts (e.g., “ever/never used,” “age at first use”), researchers harmonize these phenotypes for meta-analysis, often collapsing them into dichotomous measures.^[1]Longitudinal studies, such as those that track age at first cannabis use using Cox proportional hazards regression, account for censored observations (individuals who had not initiated use by the last assessment) and adjust for factors like birth cohort to manage temporal differences in prevalence and policy.^[3] Despite variations in cohort sampling, drug policies, and availability, meta-analyses consistently show that genetic effects tend to be in the same direction across samples, with no significant between-cohort heterogeneity for top genetic variants.^[3]

Ancestry-Specific Findings and Generalizability

Cross-population comparisons and the generalizability of findings are critical considerations in cannabis use studies. While large-scale genetic studies have predominantly focused on populations of European ancestry to maximize sample size and statistical power, the prevalence of lifetime cannabis use can vary widely across different populations and geographic locations, ranging from 1% to 92% in discovery samples.^[1] This variability is attributed to differences in recruitment strategies, cultural backgrounds, temporal changes, and drug availability across countries.^[1] Although some replication efforts have included cohorts of other ancestries, such as an African American cohort in one study, the generalizability of findings from European-centric GWAS to other ethnic groups remains an area requiring further investigation.^[1] Future research is needed to determine whether identified genetic associations are consistent across diverse populations and to explore population-specific effects that may be influenced by unique genetic architectures and environmental factors.

Molecular Signaling and Ion Channel Dynamics

Cannabis use involves complex molecular signaling pathways, particularly those governing ion channel dynamics and intracellular cascades. The_ATP2C2_gene, which encodes a calcium-transporting ATPase, has been identified in genome-wide association studies as a significant predictor of age at first cannabis use.^[3] This suggests a crucial role for intracellular calcium signaling mechanisms in the initiation and development of substance use disorders, where dysregulation of these pathways can alter neuronal excitability and synaptic plasticity, fundamental processes implicated in addictive behaviors.

Beyond calcium, other ion channels also contribute to the neurobiological landscape of cannabis use. Research on opioid dependence has highlighted the involvement of potassium pathways, suggesting that similar mechanisms of potassium signaling may also play a role in the broader context of addiction, including to cannabis.^[16] Furthermore, the _CHRNA2_gene, which codes for a nicotinic acetylcholine receptor subunit, has been implicated in cannabis use disorder.^[13]Activation of such receptors can trigger intracellular signaling cascades that modulate neurotransmitter release and neuronal network activity, thereby influencing an individual’s susceptibility to cannabis use and progression to disorder.

Genetic Regulation and Transcriptional Control

The susceptibility to cannabis use is profoundly influenced by genetic regulatory mechanisms, including gene expression and transcriptional control. Studies have identified several candidate genomic regions and specific genes, such as_ZNF181_ and _ZNF766_ on chromosome 19, which show strong association signals in gene-based analyses of cannabis initiation.^[9]As zinc finger proteins, these genes often function as transcription factors, directly regulating the expression of other genes involved in neuronal development, signaling, or metabolism, thereby establishing a molecular basis for individual differences in cannabis use patterns.

Further insights into gene regulation come from analyses integrating expression quantitative trait loci (eQTL) with genome-wide association studies, revealing genes with genetically predicted expression levels associated with cannabis use.^[2] For instance, _CADM2_, with its top associated SNP *rs2875907 *, exhibits differential expression across various tissues, linking genetic variation to altered gene activity and subsequent behavioral phenotypes.^[2]These regulatory mechanisms highlight how genetic predispositions can alter cellular machinery, influencing cellular responses to cannabinoids and ultimately contributing to the complex etiology of cannabis use.

Systems-Level Integration and Neuropsychiatric Overlap

Cannabis use is a complex trait, characterized by systems-level integration of numerous genetic and environmental factors, where many variants each exert small effect sizes.^[17] This polygenic architecture necessitates understanding pathway crosstalk and network interactions, as genetically predicted expression levels of multiple genes, often with high levels of co-expression in specific regions, collectively contribute to an individual’s risk.^[2]Such intricate network interactions suggest that the impact of cannabis use extends beyond individual molecular pathways, influencing broader biological systems and emergent properties of brain function.

A critical aspect of this systems-level integration involves the significant genetic overlap between cannabis use and various psychiatric traits, including a causal influence of schizophrenia.^[2]This suggests shared underlying biological mechanisms and pathway dysregulation that contribute to the comorbidity observed between cannabis use behaviors and mental health conditions. Understanding these network interactions and hierarchical regulation within the brain can uncover potential therapeutic targets by identifying convergent pathways that are perturbed in both cannabis use and psychiatric vulnerabilities.

Frequently Asked Questions About Cannabis Use

These questions address the most important and specific aspects of cannabis use based on current genetic research.

---

1. My parents used cannabis; am I more likely to try it?

Yes, your genetics play a significant role in whether you try cannabis, with twin studies suggesting 40-48% of the risk for initiation is inherited. This means if your parents used it, you might have a higher genetic predisposition. However, shared environmental factors like cannabis availability and how your parents monitored you also contribute a lot to this risk.

2. Why do some friends get hooked on cannabis, but others don’t?

It’s largely due to individual genetic differences, even if the initial exposure is similar. While many people use cannabis occasionally, about 1 in 10 can develop dependence, and there’s a notable overlap in the genetic risks for just using cannabis and developing a use disorder. This means some people are genetically more vulnerable to progressing to problematic use.

3. I smoke cigarettes; does that make me more prone to cannabis use?

Yes, there’s a strong genetic link between smoking cigarettes and cannabis use. Research shows a significant genetic correlation, meaning some of the same genetic factors that influence your likelihood to smoke cigarettes also increase your predisposition to use cannabis. This suggests a shared underlying genetic vulnerability to both substances.

4. Does my family history of depression mean cannabis is riskier for me?

Yes, your family history of depression could indicate a higher risk. There are genetic correlations between cannabis use and various psychiatric conditions, including depression, schizophrenia, and bipolar disorder. This means if you have a genetic predisposition to depression, you might also have genetic factors that make cannabis use more impactful or risky for your mental health.

5. Can good parenting really stop my kids from trying cannabis?

Yes, good parenting can play a substantial role, even with genetic predispositions. While genetics account for a significant portion of the risk, shared environmental factors like parental monitoring and the availability of cannabis also contribute greatly to whether your children try it. These environmental factors can help mitigate genetic risks.

6. Does where I live, like if cannabis is legal, affect my risk?

Yes, the environment where you live and the legality of cannabis can influence your risk. Shared environmental factors, such as the availability of cannabis in your area and local drug policies, contribute to the overall risk of use. These external factors interact with your genetic predispositions, influencing how likely you are to be exposed and use cannabis.

7. My sibling and I both tried cannabis; why did I struggle more?

Individual genetic differences likely play a role in why you struggled more than your sibling, even with similar exposure. While you share many genes, specific genetic variants can influence your unique susceptibility to developing dependence or experiencing adverse effects. There’s a clear overlap in genetic risks for initial use and developing a cannabis use disorder, which can vary between siblings.

8. Does my background, like my ethnicity, change my cannabis risk?

It’s possible, but current research has limitations here. Most large-scale genetic studies on cannabis use have primarily focused on individuals of European ancestry. This means that the genetic insights we have might not fully apply to people from other ethnic backgrounds, and your specific ancestry could involve different risk factors.

9. I’m generally healthy; does that make cannabis less risky for me?

Not necessarily, as your overall health doesn’t fully capture your genetic predispositions related to cannabis. Genes implicated in cannabis use have also been associated with a broad range of other traits, including BMI or obesity (like theSH2B1gene), alcohol use, and even intelligence. So, while you might feel healthy, specific genetic factors could still influence your individual risk profile for cannabis use and its effects.

10. Is it true that cannabis can make mental health issues worse for some?

Yes, it’s true that cannabis use is associated with an increased risk for certain psychiatric outcomes. This includes conditions like psychosis, schizophrenia, and mania, especially for those with existing genetic predispositions. Early cannabis use can also affect how genetic risks for schizophrenia influence brain development.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Stringer S, et al. “Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium.”Transl Psychiatry, 2016.

[2] Pasman, J. A. et al. “GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia.”Nature Neuroscience, vol. 21, no. 9, 2018, pp. 1161-1171.

[3] Minica, C. C. et al. “GENOME-WIDE ASSOCIATION META-ANALYSIS OF AGE AT FIRST CANNABIS USE.”Addiction, vol. 113, no. 10, 2018, pp. 1827-1840.

[4] Pasman JA, et al. “GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia.”Nat Neurosci, 2019.

[5] Haas, C. B. “Assessing the associations between known genetic variants and substance use in people with HIV in the United States.” PLoS One, 2023.

[6] Verweij, K. J. H., et al. “Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies.”Addiction, vol. 105, no. 3, 2010, pp. 417–30.

[7] Agrawal, Arpana, et al. “Illicit drug use and abuse/dependence: modeling of two-stage variables using the CCC approach.” Addictive Behaviors, vol. 30, no. 5, 2005, pp. 1043–48.

[8] Budney, Alan J., et al. “Marijuana dependence and its treatment.” Addiction Science & Clinical Practice, vol. 4, no. 1, 2007, p. 4.

[9] Minica, C. C. et al. “Heritability, SNP- and Gene-Based Analyses of Cannabis Use Initiation and Age at Onset.”Behavior Genetics, vol. 45, no. 5, 2015, pp. 503–513.

[10] Lynskey, M. T., et al. “Early onset cannabis use and progression to other drug use in a sample of Dutch twins.”Behavior Genetics, vol. 36, no. 2, 2006, pp. 195–200.

[11] Gillespie, N. A., et al. “Pathways to cannabis abuse: a multi-stage model from cannabis availability, cannabis initiation and progression to abuse.” Addiction, vol. 104, no. 3, 2009, pp. 430–438.

[12] Stringer, S., et al. “Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium.”Translational Psychiatry, vol. 7, no. 3, 2017, p. e1071.

[13] Demontis, D. et al. “Genome-wide association study implicates CHRNA2 in cannabis use disorder.”Addiction, vol. 112, no. 5, 2017, pp. 883-893.

[14] Soler Artigas, M., et al. “Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality.”Molecular Psychiatry, 2019.

[15] Thorgeirsson, Thorgeir E., et al. “Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior.” Nature Genetics, vol. 42, no. 5, 2010, pp. 448-453.

[16] Gelernter, J. et al. “Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways.”Biological Psychiatry, vol. 76, no. 1, 2014, pp. 66–74.

[17] Stringer, S. et al. “Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium.”Translational Psychiatry, vol. 5, no. 3, 2015, e532.